Literature DB >> 7750987

Characterization of eukaryotic protein L7 as a novel autoantigen which frequently elicits an immune response in patients suffering from systemic autoimmune disease.

A von Mikecz1, P Hemmerich, H H Peter, U Krawinkel.   

Abstract

Autoantibodies targeted against cellular proteins and nucleic acids are a common feature of autoimmune diseases. In this study, we show that ribosomal protein L7 is a novel autoantigen in patients suffering from systemic lupus erythematosus (SLE) and other connective tissue diseases. From 24 patients diagnosed as having SLE, 18 produce antibodies which precipitate in vitro translated L7 protein. The anti-L7 titer appears to correlate with the active state of the disease. Anti-L7 autoantibodies were also detected in 7 of 13 patients with mixed connective tissue disease (MCTD), 2 of 7 patients with rheumatoid arthritis (RA), 1 of 4 patients with Sjögren's syndrome (SS) and in 1 patient with progressive systemic sclerosis (PSS). Anti-L7 autoantibodies belong to the IgG-class and detect specifically at least two epitopes on the L7 molecule, as shown by immunoprecipitation and immunoblotting. The epitope(s) of the highly conserved C-terminal region are preferentially recognized. Utilizing rabbit anti-L7 serum, autoimmune sera and affinity-purified anti-L7 autoantibodies in immunoblotting, and rabbit and chicken anti-L7 antibodies in indirect immunofluorescence, we detect L7 protein in the nuclei and in the cytoplasm of various cell-lines. Yet unlike most integral structural components of ribosomes, L7 is absent from nucleoli.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7750987     DOI: 10.1016/S0171-2985(11)80413-4

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  4 in total

1.  Autoantibodies against eukaryotic protein L7 in patients suffering from systemic lupus erythematosus and progressive systemic sclerosis: frequency and correlation with clinical, serological and genetic parameters. The SLE Study Group.

Authors:  E Neu; A H von Mikecz; P H Hemmerich; H H Peter; M Fricke; H Deicher; E Genth; U Krawinkel
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

2.  Autoantigenic epitopes on eukaryotic L7.

Authors:  A H von Mikecz; P H Hemmerich; H H Peter; U Krawinkel
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

3.  A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci.

Authors:  Eimear E Kenny; Itsik Pe'er; Amir Karban; Laurie Ozelius; Adele A Mitchell; Sok Meng Ng; Monica Erazo; Harry Ostrer; Clara Abraham; Maria T Abreu; Gil Atzmon; Nir Barzilai; Steven R Brant; Susan Bressman; Edward R Burns; Yehuda Chowers; Lorraine N Clark; Ariel Darvasi; Dana Doheny; Richard H Duerr; Rami Eliakim; Nir Giladi; Peter K Gregersen; Hakon Hakonarson; Michelle R Jones; Karen Marder; Dermot P B McGovern; Jennifer Mulle; Avi Orr-Urtreger; Deborah D Proctor; Ann Pulver; Jerome I Rotter; Mark S Silverberg; Thomas Ullman; Stephen T Warren; Matti Waterman; Wei Zhang; Aviv Bergman; Lloyd Mayer; Seymour Katz; Robert J Desnick; Judy H Cho; Inga Peter
Journal:  PLoS Genet       Date:  2012-03-08       Impact factor: 5.917

4.  FM-test: a fuzzy-set-theory-based approach to differential gene expression data analysis.

Authors:  Lily R Liang; Shiyong Lu; Xuena Wang; Yi Lu; Vinay Mandal; Dorrelyn Patacsil; Deepak Kumar
Journal:  BMC Bioinformatics       Date:  2006-12-12       Impact factor: 3.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.